Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment

Submitted: 17 July 2016
Accepted: 11 October 2016
Published: 16 December 2016
Abstract Views: 2964
PDF: 766
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

We observed a 69-year old man suffering from HLA B27 ankylosing spondylitis with persistent night back pain. 18F-FDG-PET/CT showed an increased metabolism at the level of the spinal space of L2-L3, L3-L4 with increased uptake compatible with spondylodiscitis. He started therapy with etanercept 50 mg/week. After six months of treatment repeated testing showed no uptake of the discs and vertebral bodies.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

M. Benucci, Rheumatology Unit, S. Giovanni di Dio Hospital, Firenze
Internal Medicine

How to Cite

Benucci, M., Damiani, A., Arena, A., Infantino, M., Manfredi, M., & Li Gobbi, F. (2016). Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment. Reumatismo, 68(3), 163–165. https://doi.org/10.4081/reumatismo.2016.911

Similar Articles

1 2 3 4 5 6 7 8 9 > >> 

You may also start an advanced similarity search for this article.